First Wave BioPharma
FWBI

股本结构

单位：万股
公告日期 2024-05-13 2024-05-13 2024-05-14 2024-03-29 2024-03-04 2024-03-29
证券总股本 275.01 247.51 202.52 202.52 173.59 156.10
普通股本 275.01 247.51 202.52 202.52 173.59 156.10
优先股 未披露 未披露 0.05 未披露 未披露 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2024-05-14 2024-05-10 2024-03-31 2024-03-27 2024-03-06 2023-12-31
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2024-05-13 275.01 未披露
更多>>
Common stock offered 275,000 shares by the company
2024-05-14
2024-05-13 247.51 未披露 定期报告 2024-05-10
2024-05-14 202.52 0.05
更多>>
From January 1, 2024 to March 31, 2024 Issuance of common stock, pre-funded warrants and warrants in registered direct offering, net of issuance costs Issuance of common stock upon acquisition of IMGX Issuance of common stock to financial advisors Exercise of pre-funded warrants into common stock Conversion of Series B preferred shares into common stock Common stock issued to consultants Issuance of common stock from RSU vest
2024-03-31
2024-03-29 202.52 未披露 定期报告 2024-03-27
2024-03-04 173.59 未披露
更多>>
Common stock offered 173,100 shares by the company
2024-03-06
2024-03-04 156.28 未披露 定期报告 2024-03-01
2024-03-29 156.10 0.05
更多>>
From January 1, 2023 to December 31, 2023 Common stock issued to consultants Effect of cancelled shares from the 1-for-20 reverse stock split Exercise of pre-funded warrants into common stock Conversion of Series B preferred shares into common stock Issuance of common stock from RSU vest Issuance of common stock in connection with the exercise of warrants in the September 2023 Inducement Offering, net of offering costs Issuance of common stock in connection with the exercise of warrants in the June 2023 Inducement Offering, net of offering costs Issuance of common stock, pre-funded warrants and warrants in the March 2023 Offering, net of issuance costs Issuance of common stock, pre-funded warrants and warrants in the July 2023 offering, net of issuance costs Issuance of common stock in connection with the exercise of warrants in the December 2023 Inducement Offering, net of offering costs Effect of cancelled shares from the 1-for-7 reverse stock split
2023-12-31
2024-01-08 156.10 未披露 定期报告 2023-12-28
2023-12-14 67.50 未披露
更多>>
First Wave BioPharma, Inc. announced that its Board of Directors approved a 1-for-20 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on Monday, December 18, 2023.
2023-12-18
2023-11-13 1350.00 未披露 定期报告 2023-10-16
2023-11-13 1346.35 0.05
更多>>
From July 1, 2023 to September 30, 2023 Issuance of common stock, pre-funded warrants and warrants in July 2023 offering, net of issuance costs Common stock issued to consultants Issuance of common stock in connection with the exercise of warrants in the September 2023 Inducement Offering, net of offering costs Conversion of Series B preferred shares into common stock Issuance of common stock from RSU vest Exercise of pre-funded warrants into common stock
2023-09-30
2023-09-22 1346.35 未披露 定期报告 2023-09-18
2023-08-14 715.22 未披露 定期报告 2023-08-10
2023-07-20 481.90 未披露
更多>>
Common Stock offered 610,000 shares by the company
2023-07-31
2023-06-20 420.90 0.05 定期报告 2023-06-16
2023-06-05 194.67 0.05 定期报告 2023-05-25
2023-05-15 181.37 未披露 定期报告 2023-05-05
2023-05-12 154.96 0.05
更多>>
From January 1, 2023 to March 31, 2023 Conversion of Series B preferred shares into common stock Issuance of common stock, pre-funded warrants and warrants in private placement, net of issuance costs Exercise of pre-funded warrants into common stock Effect of cancelled shares from the 1-for-7 reverse stock split
2023-03-31
2023-03-20 154.96 未披露 定期报告 2023-03-16
2023-01-17 99.50 未披露
更多>>
On January 13, 2023, the Company filed the Amendment to its Charter with the Secretary of State of the State of Delaware to effect a reverse stock split of its Common Stock at a ratio of 1-to-7 (the “Reverse Stock Split”).
2023-01-18
2023-01-17 696.50 未披露 定期报告 2023-01-17
2022-12-16 580.47 0.58 定期报告 2022-12-08
2022-12-02 580.47 未披露 定期报告 2022-12-01
2022-11-14 579.54 未披露 定期报告 2022-11-10
2022-10-11 574.54 未披露
更多>>
the company is offering 255,000 shares Common Stock
2022-10-11
2022-11-14 230.70 0.06
更多>>
From July 1, 2022 to September 30, 2022 Issuance of common stock at-the-market for cash, net of offering costs Issuance of common stock from the conversion of Series D preferred stock Issuance of common stock from the conversion of Series E preferred stock Effect of cancelled shares from the 30-for-1 reverse stock split
2022-09-30
2022-09-14 230.70 未披露 定期报告 2022-09-09
2022-08-25 140.00 未披露
更多>>
On August 25, 2022, First Wave BioPharma, Inc. announced that it intends to effect a reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock (the “Common Stock”) at a ratio of 1 post-split share for every 30 pre-split shares. First Wave’s Common Stock will continue to be traded on The Nasdaq Capital Market under the symbol FWBI and will begin trading on a split-adjusted basis when the market opens on Friday, August 26, 2022, under a new CUSIP number, 33749P200.
2022-08-26
2022-07-28 4159.03 0.09 定期报告 2022-07-25
2022-07-25 4159.03 0.03 定期报告 2022-07-15
2022-08-15 2269.98 0.06
更多>>
From April 1, 2022 to June 30, 2022 Conversion of Series B preferred shares into common stock Issuance of common stock at-the-market for cash, net of offering costs
2022-06-30
2022-05-24 2076.28 未披露 定期报告 2022-05-24
2022-05-23 2163.53 未披露 定期报告 2022-05-19
2022-05-23 2154.88 0.06
更多>>
From January 1, 2022 to March 31, 2022 Issuance of common stock, pre-funded warrants and warrants in registered direct offering, net of issuance costs Exercise of pre-funded warrants into common stock Conversion of Series B preferred shares into common stock Common stock issued to consultants
2022-03-31
2022-03-31 1670.06 未披露 定期报告 2022-03-28
2022-03-02 2144.41 未披露
更多>>
1.Shares of Common Stock offered by 1,650,000 shares of common stock 2.The above discussion is based on 14,945,905 shares of common stock outstanding as of February 18, 2022
2022-03-02
2022-03-31 1485.58 0.07
更多>>
From January 1, 2021 to December 31, 2021 Issuance of Series C preferred stock and warrants for cash, net of offering costs Issuance of Series C preferred stock for license acquired Issuance of Series C preferred stock upon exchange of Series B preferred stock Common stock and pre-funded warrants issued upon conversion of Series C preferred stock Issuance of common stock upon exchange of Series B preferred stock Common stock issued upon conversion of Series B preferred stock Issuance of common stock, pre-funded warrants and warrants for cash, net of offering costs Effect of 10-for-1 reverse stock split Issuance of common stock at-the-market for cash, net of offering costs Common stock issued for intellectual property acquired, net Common stock cancelled in connection with acquisition of First Wave Bio, Inc. Common stock issued upon exercise of warrants Common stock and warrants issued to consultants Settlement with former placement agent
2021-12-31
2021-11-19 1246.08 未披露 定期报告 2021-11-05
2021-11-15 1111.52 0.07
更多>>
From July 1, 2021 to September 30, 2021 Issuance of common stock, pre-funded warrants and warrants for cash, net of offering costs Issuance of common stock at-the-market for cash, net of offering costs Effect of cancelled shares from the 10-for-1 reverse stock split Common stock issued for intellectual property acquired, net Common stock cancelled in connection with acquisition of First Wave Bio, Inc. Common stock and warrants issued to consultants
2021-09-30
2021-09-13 996.52 未披露
更多>>
On September 13, 2021, AzurRx BioPharma, Inc., a Delaware corporation (the “Company”), Alpha Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), First Wave Bio, Inc., a Delaware corporation (“First Wave”), and Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as the representative of the stockholders and option holders of First Wave (the “Stockholders”), entered into an Agreement and Plan of Merger (the “Merger Agreement”). Following the Merger, and after giving effect to the 10-for-1 reverse stock split, there will be an aggregate of approximately 9,965,174 shares of Common Stock outstanding.
2021-09-13
2021-08-16 9326.19 未披露 定期报告 2021-08-13
2021-07-27 9189.83 未披露
更多>>
1.Shares of common stock offered 9,090,910 shares. 2.The above discussion is based on 82,807,351 shares of common stock outstanding as of July 19, 2021.
2021-07-27
2021-07-22 8280.74 未披露 定期报告 2021-07-19
2021-08-16 8258.51 0.07
更多>>
From April 1, 2021 to June 30, 2021 Issuance of Series C preferred stock upon exchange of Series B preferred stock Common stock and pre-funded warrants issued upon conversion of Series C preferred stock Issuance of common stock at-the-market for cash, net of offering costs Common stock issued upon exercise of warrants Common stock and warrants issued to consultants
2021-06-30
2021-05-26 7857.51 0.09 定期报告 2021-05-21
2021-05-24 7857.51 未披露 定期报告 2021-05-18
2021-05-24 7492.69 0.12
更多>>
From January 1, 2021 To March 31, 2021 Issuance of Series C preferred stock and warrants for cash, net of offering costs Issuance of Series C preferred stock to settle liability arising from acquisition Issuance of Series C preferred stock upon exchange of Series B preferred stock Common stock issued upon conversion of Series B preferred stock Common stock and pre-funded warrants issued upon conversion of Series C preferred stock Issuance of common stock, pre-funded warrants and warrants for cash, net of offering costs Common stock issued upon exercise of warrants Common stock and warrants issued to consultants Issuance of common stock in connection with settlement with former investment bank
2021-03-31
2021-03-31 7443.94 未披露 定期报告 2021-03-29
2021-03-10 7100.69 未披露
更多>>
1.Shares of Common Stock offered by the company 5,800,000. 2.The above discussion is based on 65,206,854 shares of common stock outstanding as of March 5, 2021.
2021-03-10
2021-03-09 6520.69 未披露 定期报告 2021-03-05
2021-02-11 5341.87 0.96 定期报告 2021-02-10
2021-02-01 4943.71 0.99 定期报告 2021-01-29
2021-01-13 3884.99 1.12 定期报告 2021-01-11
2021-01-20 3125.04 未披露 定期报告 2021-01-04
2021-01-13 3884.99 未披露 定期报告 2021-01-01
2021-01-05 3095.03 未披露 定期报告 2020-12-30
2020-11-16 3041.21 未披露 定期报告 2020-11-13
2020-11-16 2888.20 0.29
更多>>
From January 1, 2020 to September 30, 2020 Issuance of Series B preferred stock and warrants for cash, conversion of promissory notes, net of offering costs Conversion of Series B preferred shares into common stock Issuance of common stock for accrued dividends upon conversion of Series B preferred stock Common stock issued to settle accounts payable Common stock issued to Lincoln Park for Equity Purchase agreement Common stock issued to consultants
2020-09-30
2020-07-27 2850.29 0.29 定期报告 2020-07-23
2020-08-14 2850.29 未披露
更多>>
From January 1, 2020 to June 30, 2020 Common stock issued to settle accounts payable Common stock issued to consultants Common stock issued to Lincoln Park for Equity Purchase agreement
2020-06-30
2020-05-15 2820.29 未披露 定期报告 2020-05-14
2020-04-29 2745.77 未披露 定期报告 2020-04-27
2020-05-15 2715.77 未披露
更多>>
From January 1, 2020 to March 31, 2020 Common stock issued to settle related payable accounts payable Common stock issued to consultants Common stock issued to Lincoln Park for Equity Purchase agreement
2020-03-31
2020-03-30 2713.15 未披露 定期报告 2020-03-30
2020-03-30 2680.05 未披露
更多>>
From December 31, 2018 to December 31, 2019 Common stock issued from public offerings Common stock issued to consultants Common stock issued to Mayoly for patents Common stock issued to Lincoln Park for Equity Purchase agreement Restricted common stock granted to employees and directors
2019-12-31
2019-12-31 2664.23 未披露 定期报告 2019-12-27
2019-11-14 2615.51 未披露
更多>>
From June 30, 2019 to September 30, 2019 Common stock issued from public offerings Common stock issued to consultants Common stock issued to Mayoly for patents Restricted stock granted to employees/directors
2019-09-30
2019-08-13 2610.34 未披露 定期报告 2019-08-12
2019-07-22 2610.38 未披露 定期报告 2019-07-22
2019-07-17 2110.38 未披露 定期报告 2019-07-16
2019-08-13 2110.34 未披露
更多>>
From March 31, 2019 to June 30, 2019 Common stock issued from public offerings Common stock issued to consultants Common stock issued to Mayoly for patents Restricted stock granted to employees/directors
2019-06-30
2019-05-14 2106.01 未披露 定期报告 2019-05-13
2019-04-26 1983.29 未披露 定期报告 2019-04-25
2019-05-15 1853.80 未披露
更多>>
from December 31, 2018 to March 31, 2019 Common stock issued to consultants Common stock issued to Mayoly for patents Restricted stock granted to employees/directors
2019-03-31
2019-04-01 1770.49 未披露
更多>>
from December 31, 2017 to December 31, 2018 Common stock issued from public offering Common stock issued to consultants Common stock issued for warrant exercises Common stock issued for purchase of Protea assets from bankruptcy Restricted stock granted to employees/directors Convertible debt converted into common stock
2018-12-31
2018-11-09 1694.05 未披露
更多>>
From January 1, 2018 to September 30, 2018 Common stock issued from public offering Common stock issued to consultants Common stock issued for warrant exercises Restricted stock granted to employees/directors Convertible debt converted into common stock
2018-09-30
2018-08-13 1691.05 未披露 定期报告 2018-08-10
2018-08-13 1679.24 未披露
更多>>
From January 1, 2018 to June 30, 2018 Common stock issued from public offering Common stock issued to consultants Common stock issued for warrant exercises Restricted stock granted to employees/directors Convertible debt converted into common stock
2018-06-30
2018-05-14 1676.24 未披露 定期报告 2018-05-14
2018-05-14 1260.24 未披露
更多>>
From January 1, 2018 to March 31, 2018 Common stock issued to consultants Common stock issued for warrant exercises Restricted stock granted to employees/directors Convertible debt converted into common stock
2018-03-31
2018-03-16 1257.24 未披露 定期报告 2018-03-15
2018-03-16 1204.26 未披露
更多>>
from December 31, 2016 to December 31, 2017 Common stock issued in private placement Restricted stock granted to employees/directors Restricted stock granted to consultants Convertible debt converted into common stock Common stock issued for convertible debt extension Common stock subscribed
2017-12-31
2017-11-01 1155.41 未披露 定期报告 2017-10-31
2017-10-11 1147.09 未披露 定期报告 2017-10-10
2017-11-13 1142.17 未披露
更多>>
From January 1, 2017 to September 30, 2017 Common stock and warrants issued from private placement Common stock issued from conversion of convertible debt Restricted stock granted to consultants
2017-09-30
2017-10-20 1142.17 未披露 定期报告 2017-09-29
2017-07-21 1123.24 未披露 定期报告 2017-07-19
2017-08-14 1111.82 未披露
更多>>
From January 1, 2017 to June 30, 2017 Common stock and warrants issued from private placement Restricted stock granted to consultants
2017-06-30
2017-03-31 963.11 未披露
更多>>
From December 31, 2015 to December 31, 2016 Common stock issued Preferred stock converted into common stock Convertible debt converted into common stock
2016-12-31
2016-10-13 963.11 未披露 定期报告 2016-10-11
2016-09-06 602.89 未披露
更多>>
From December 31, 2015 to June 30, 2016 Preferred stock converted into common stock
2016-06-30
Common stock offered 275,000 shares by the company
From January 1, 2024 to March 31, 2024 Issuance of common stock, pre-funded warrants and warrants in registered direct offering, net of issuance costs Issuance of common stock upon acquisition of IMGX Issuance of common stock to financial advisors Exercise of pre-funded warrants into common stock Conversion of Series B preferred shares into common stock Common stock issued to consultants Issuance of common stock from RSU vest
Common stock offered 173,100 shares by the company
From January 1, 2023 to December 31, 2023 Common stock issued to consultants Effect of cancelled shares from the 1-for-20 reverse stock split Exercise of pre-funded warrants into common stock Conversion of Series B preferred shares into common stock Issuance of common stock from RSU vest Issuance of common stock in connection with the exercise of warrants in the September 2023 Inducement Offering, net of offering costs Issuance of common stock in connection with the exercise of warrants in the June 2023 Inducement Offering, net of offering costs Issuance of common stock, pre-funded warrants and warrants in the March 2023 Offering, net of issuance costs Issuance of common stock, pre-funded warrants and warrants in the July 2023 offering, net of issuance costs Issuance of common stock in connection with the exercise of warrants in the December 2023 Inducement Offering, net of offering costs Effect of cancelled shares from the 1-for-7 reverse stock split
First Wave BioPharma, Inc. announced that its Board of Directors approved a 1-for-20 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on Monday, December 18, 2023.
From July 1, 2023 to September 30, 2023 Issuance of common stock, pre-funded warrants and warrants in July 2023 offering, net of issuance costs Common stock issued to consultants Issuance of common stock in connection with the exercise of warrants in the September 2023 Inducement Offering, net of offering costs Conversion of Series B preferred shares into common stock Issuance of common stock from RSU vest Exercise of pre-funded warrants into common stock
Common Stock offered 610,000 shares by the company
From January 1, 2023 to March 31, 2023 Conversion of Series B preferred shares into common stock Issuance of common stock, pre-funded warrants and warrants in private placement, net of issuance costs Exercise of pre-funded warrants into common stock Effect of cancelled shares from the 1-for-7 reverse stock split
On January 13, 2023, the Company filed the Amendment to its Charter with the Secretary of State of the State of Delaware to effect a reverse stock split of its Common Stock at a ratio of 1-to-7 (the “Reverse Stock Split”).
the company is offering 255,000 shares Common Stock
From July 1, 2022 to September 30, 2022 Issuance of common stock at-the-market for cash, net of offering costs Issuance of common stock from the conversion of Series D preferred stock Issuance of common stock from the conversion of Series E preferred stock Effect of cancelled shares from the 30-for-1 reverse stock split
On August 25, 2022, First Wave BioPharma, Inc. announced that it intends to effect a reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock (the “Common Stock”) at a ratio of 1 post-split share for every 30 pre-split shares. First Wave’s Common Stock will continue to be traded on The Nasdaq Capital Market under the symbol FWBI and will begin trading on a split-adjusted basis when the market opens on Friday, August 26, 2022, under a new CUSIP number, 33749P200.
From April 1, 2022 to June 30, 2022 Conversion of Series B preferred shares into common stock Issuance of common stock at-the-market for cash, net of offering costs
From January 1, 2022 to March 31, 2022 Issuance of common stock, pre-funded warrants and warrants in registered direct offering, net of issuance costs Exercise of pre-funded warrants into common stock Conversion of Series B preferred shares into common stock Common stock issued to consultants
1.Shares of Common Stock offered by 1,650,000 shares of common stock 2.The above discussion is based on 14,945,905 shares of common stock outstanding as of February 18, 2022
From January 1, 2021 to December 31, 2021 Issuance of Series C preferred stock and warrants for cash, net of offering costs Issuance of Series C preferred stock for license acquired Issuance of Series C preferred stock upon exchange of Series B preferred stock Common stock and pre-funded warrants issued upon conversion of Series C preferred stock Issuance of common stock upon exchange of Series B preferred stock Common stock issued upon conversion of Series B preferred stock Issuance of common stock, pre-funded warrants and warrants for cash, net of offering costs Effect of 10-for-1 reverse stock split Issuance of common stock at-the-market for cash, net of offering costs Common stock issued for intellectual property acquired, net Common stock cancelled in connection with acquisition of First Wave Bio, Inc. Common stock issued upon exercise of warrants Common stock and warrants issued to consultants Settlement with former placement agent
From July 1, 2021 to September 30, 2021 Issuance of common stock, pre-funded warrants and warrants for cash, net of offering costs Issuance of common stock at-the-market for cash, net of offering costs Effect of cancelled shares from the 10-for-1 reverse stock split Common stock issued for intellectual property acquired, net Common stock cancelled in connection with acquisition of First Wave Bio, Inc. Common stock and warrants issued to consultants
On September 13, 2021, AzurRx BioPharma, Inc., a Delaware corporation (the “Company”), Alpha Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), First Wave Bio, Inc., a Delaware corporation (“First Wave”), and Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as the representative of the stockholders and option holders of First Wave (the “Stockholders”), entered into an Agreement and Plan of Merger (the “Merger Agreement”). Following the Merger, and after giving effect to the 10-for-1 reverse stock split, there will be an aggregate of approximately 9,965,174 shares of Common Stock outstanding.
1.Shares of common stock offered 9,090,910 shares. 2.The above discussion is based on 82,807,351 shares of common stock outstanding as of July 19, 2021.
From April 1, 2021 to June 30, 2021 Issuance of Series C preferred stock upon exchange of Series B preferred stock Common stock and pre-funded warrants issued upon conversion of Series C preferred stock Issuance of common stock at-the-market for cash, net of offering costs Common stock issued upon exercise of warrants Common stock and warrants issued to consultants
From January 1, 2021 To March 31, 2021 Issuance of Series C preferred stock and warrants for cash, net of offering costs Issuance of Series C preferred stock to settle liability arising from acquisition Issuance of Series C preferred stock upon exchange of Series B preferred stock Common stock issued upon conversion of Series B preferred stock Common stock and pre-funded warrants issued upon conversion of Series C preferred stock Issuance of common stock, pre-funded warrants and warrants for cash, net of offering costs Common stock issued upon exercise of warrants Common stock and warrants issued to consultants Issuance of common stock in connection with settlement with former investment bank
1.Shares of Common Stock offered by the company 5,800,000. 2.The above discussion is based on 65,206,854 shares of common stock outstanding as of March 5, 2021.
From January 1, 2020 to September 30, 2020 Issuance of Series B preferred stock and warrants for cash, conversion of promissory notes, net of offering costs Conversion of Series B preferred shares into common stock Issuance of common stock for accrued dividends upon conversion of Series B preferred stock Common stock issued to settle accounts payable Common stock issued to Lincoln Park for Equity Purchase agreement Common stock issued to consultants
From January 1, 2020 to June 30, 2020 Common stock issued to settle accounts payable Common stock issued to consultants Common stock issued to Lincoln Park for Equity Purchase agreement
From January 1, 2020 to March 31, 2020 Common stock issued to settle related payable accounts payable Common stock issued to consultants Common stock issued to Lincoln Park for Equity Purchase agreement
From December 31, 2018 to December 31, 2019 Common stock issued from public offerings Common stock issued to consultants Common stock issued to Mayoly for patents Common stock issued to Lincoln Park for Equity Purchase agreement Restricted common stock granted to employees and directors
From June 30, 2019 to September 30, 2019 Common stock issued from public offerings Common stock issued to consultants Common stock issued to Mayoly for patents Restricted stock granted to employees/directors
From March 31, 2019 to June 30, 2019 Common stock issued from public offerings Common stock issued to consultants Common stock issued to Mayoly for patents Restricted stock granted to employees/directors
from December 31, 2018 to March 31, 2019 Common stock issued to consultants Common stock issued to Mayoly for patents Restricted stock granted to employees/directors
from December 31, 2017 to December 31, 2018 Common stock issued from public offering Common stock issued to consultants Common stock issued for warrant exercises Common stock issued for purchase of Protea assets from bankruptcy Restricted stock granted to employees/directors Convertible debt converted into common stock
From January 1, 2018 to September 30, 2018 Common stock issued from public offering Common stock issued to consultants Common stock issued for warrant exercises Restricted stock granted to employees/directors Convertible debt converted into common stock
From January 1, 2018 to June 30, 2018 Common stock issued from public offering Common stock issued to consultants Common stock issued for warrant exercises Restricted stock granted to employees/directors Convertible debt converted into common stock
From January 1, 2018 to March 31, 2018 Common stock issued to consultants Common stock issued for warrant exercises Restricted stock granted to employees/directors Convertible debt converted into common stock
from December 31, 2016 to December 31, 2017 Common stock issued in private placement Restricted stock granted to employees/directors Restricted stock granted to consultants Convertible debt converted into common stock Common stock issued for convertible debt extension Common stock subscribed
From January 1, 2017 to September 30, 2017 Common stock and warrants issued from private placement Common stock issued from conversion of convertible debt Restricted stock granted to consultants
From January 1, 2017 to June 30, 2017 Common stock and warrants issued from private placement Restricted stock granted to consultants
From December 31, 2015 to December 31, 2016 Common stock issued Preferred stock converted into common stock Convertible debt converted into common stock
From December 31, 2015 to June 30, 2016 Preferred stock converted into common stock
同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。